Monogram Technologies Inc. - Common Stock (MGRM)

Management Anticipates That it has Sufficiently Addressed the FDA's Concerns to Mitigate the Need for a Clinical Data Request

AUSTIN, TEXAS / ACCESSWIRE / December 2, 2024 / Monogram Technologies Inc. (NASDAQMGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced completed purchases of MGRM common stock on the open market by certain related parties including Chief Financial Officer Noel Knape, totaling approximately $1 million. Additional details can be found on the Form 8-K filed today by the Company under Item 8.01 Other Events.

Closed an Upsized and Oversubscribed $13 Million Public Offering to Fund Near-term Commercialization Milestones

AUSTIN, TX / ACCESSWIRE / November 12, 2024 / Monogram Technologies Inc. (NASDAQMGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a conference call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the third quarter ended September 30, 2024 and to discuss key milestones. A press release detailing these results will be issued prior to the call.

Award from Medical Tech Outlook Highlights Monogram's mBôs TKA System

AUSTIN, TX / ACCESSWIRE / October 16, 2024 / Monogram Technologies Inc. (NASDAQMGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will attend the LD Micro Main Event XVII Conference being held at the Luxe Sunset Blvd Hotel in Los Angeles, CA October 29 - 30, 2024.

Company Has 180 Days From Receipt to Produce Additional Information

Company to Conduct Clinical Trial to Produce Additional Information Within 180 Days

Submitted FDA 510(k) Application and Passed FDA Administrative Review for the mBôs TKA System

AUSTIN, TX / ACCESSWIRE / October 2, 2024 / Monogram Technologies Inc. (NASDAQMGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, announced today that the Company closed the previously announced 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") continuous offering on October 1, 2024. The Company sold 5,790,479 units, with each unit consisting of (a) one share of the Company's Series D Preferred Stock and (b) one common stock purchase warrant to purchase one share of the Company's common stock, $0.001 par value per share (the "Common Stock"), for a total of 5,790,479 shares of the Company's Series D Preferred Stock and warrants to purchase an aggregate of 5,790,479 shares of the Company's Common Stock (and shares of Common Stock underlying shares of Series D Preferred Stock, PIK dividends on Series D Preferred Stock, and all such warrants). The Company received gross proceeds of approximately $13 million in connection with this offering.

AUSTIN, TX / ACCESSWIRE / October 1, 2024 / Monogram Technologies Inc. (NASDAQMGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, announced today the declaration of a dividend of $0.0255 per share payable to holders of record of shares of the Company's 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") at the close of business on October 1, 2024. In addition, the Company announced that it will be paying the dividend in kind based on the closing price of its common stock, par value $0.001 per share on September 30, 2024. Holders of record will receive the dividend on October 15, 2024. Dividends on the Series D Preferred Stock are payable quarterly in arrears to Series D Preferred Stockholders of the record, on or about the 15th day of January, April, July and October, beginning on or about October 15, 2024.

AUSTIN, TX / ACCESSWIRE / September 11, 2024 / Monogram Technologies Inc. (NASDAQMGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced an upsize of its previously announced continuous offering of units from $10 million to $12.5 million of units. Each unit consists of (a) one share of the Company's 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") and (b) one common stock purchase warrant to purchase one share of its common stock, $0.001 par value per share (the "Common Stock").

Clinical Trial Collaboration Follows 510(k) Submission and Passing of FDA Administrative Review; Preludes Planned International Launch for the mBȏs TKA System

Application was Submitted on July 19, 2024, Passed the FDA Administrative Review, and is Now Under Substantive Review

Management to Showcase Product Demonstration of mBôs Precision Robotic Surgical System and mVision Technologies

New Name Reflects Continued Evolution as an AI-Driven Robotics Company with a Strong IP Position

AUSTIN, TX / ACCESSWIRE / August 1, 2024 / Monogram Technologies Inc. (NASDAQMGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a business update conference call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the second quarter ended June 30, 2024 and to discuss key milestones. A press release detailing these results will be issued prior to the call.

AUSTIN, TX / ACCESSWIRE / July 9, 2024 / Monogram Technologies Inc. (NASDAQMGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, announced the launch of a continuous public offering of up to $10,000,000 of units at a public offering price of $2.25 (the "Public Offering"). Each unit consists of one share 8.00% Series D Redeemable Convertible Cumulative Preferred Stock and one warrant to purchase one share of common stock exercisable at $3.375 per share, which will result in net proceeds to the Company of approximately $9.25 million after payment of estimated commissions and offering expenses if all Units are sold.

Verification and Validation Testing Expected to be Largely Complete in Q2 2024; 510(k) Submission with FDA Accelerated for Second Half of 2024

CRO Expands Clinical Capabilities, Accelerating Product Pipeline Development and Commercialization Opportunities

510(k) Submission with FDA Accelerated for Early Second Half of 2024

Collaboration to Provide Monogram with Technical Resources to Drive Development and Commercialization of mBôs System

510(k) Submission with FDA On Track for Second Half of 2024

Event features Monogram's mBôs commercial robot alongside panel of orthopaedic surgeons

AUSTIN, TX / ACCESSWIRE / March 20, 2024 / Monogram Orthopaedics Inc. (NASDAQMGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, today announced management will host a business update conference call on Thursday, March 21, 2024 at 5:00 p.m. Eastern time to discuss its results for the full fiscal year ended December 31, 2023, and will be providing regulatory updates, reviewing ongoing initiatives and technology strategy, and anticipated 2024 milestones.